<DOC>
	<DOCNO>NCT00729053</DOCNO>
	<brief_summary>- Multi-Center - Randomized - Open-Label Study single agent IMO-2055 - Patients Metastatic Locally Recurrent Clear Cell Renal Carcinoma ( RCC )</brief_summary>
	<brief_title>Study IMO-2055 Metastatic Locally Recurrent Clear Cell Renal Carcinoma</brief_title>
	<detailed_description>This study 2 dose level ( 0.16 0.64 mg/kg ) IMO-2055 administered weekly subcutaneous ( SC ) injection two patient population , treatment na√Øve previously treat patient . Each dose group ( treatment naive previously treat ) randomize receive one 2 dos study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<criteria>Histologically confirm stage IV clear cell renal carcinoma metastatic locally recurrent disease surgically resectable . At least one measurable lesion Adequate organ function Any prior treatment renal cell cancer conclude least 4 week prior . If female childbearing potential , negative serum pregnancy test perform documented 14 day first dose study drug . Known untreated central nervous system ( CNS ) metastasis Preexisting autoimmune antibodymediated diseases Other significant medical disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>renal</keyword>
	<keyword>cell</keyword>
	<keyword>renal carcinoma</keyword>
	<keyword>metastatic</keyword>
	<keyword>recurrent</keyword>
	<keyword>treatment naive</keyword>
</DOC>